Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Caribou Biosciences, Inc. (CRBU) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Caribou Biosciences, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1619856.
Total stock buying since 2021: $360,747.
Total stock sales since 2021: $157,899.
Total stock option exercises since 2021: $901,402.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 37,360 | $45,051 | 10,692 | $14,433 | 0 | $0 |
| 2024 | 0 | $0 | 0 | $0 | 30,577 | $82,252 |
| 2023 | 0 | $0 | 5,627 | $35,506 | 20,000 | $59,200 |
| 2022 | 7,387 | $25,115 | 10,000 | $107,960 | 274,302 | $759,950 |
| 2021 | 133,088 | $290,581 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-03 | 20,000 | $20,400 | 0 | $0 | 0 | $0 |
| 2025-02 | 0 | $0 | 10,692 | $14,433 | 0 | $0 |
| 2025-01 | 17,360 | $24,651 | 0 | $0 | 0 | $0 |
| 2024-02 | 0 | $0 | 0 | $0 | 30,577 | $82,252 |
| 2023-06 | 0 | $0 | 0 | $0 | 10,000 | $29,600 |
| 2023-03 | 0 | $0 | 0 | $0 | 10,000 | $29,600 |
| 2023-01 | 0 | $0 | 5,627 | $35,506 | 0 | $0 |
| 2022-12 | 0 | $0 | 0 | $0 | 107,005 | $287,840 |
| 2022-10 | 0 | $0 | 10,000 | $107,960 | 5,678 | $19,305 |
| 2022-09 | 0 | $0 | 0 | $0 | 27,595 | $74,230 |
| 2022-05 | 0 | $0 | 0 | $0 | 86,694 | $204,776 |
| 2022-03 | 0 | $0 | 0 | $0 | 12,994 | $44,179 |
| 2022-02 | 0 | $0 | 0 | $0 | 24,336 | $100,020 |
| 2022-01 | 7,387 | $25,115 | 0 | $0 | 10,000 | $29,600 |
| 2021-12 | 7,263 | $19,536 | 0 | $0 | 0 | $0 |
| 2021-10 | 125,825 | $271,045 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-14 | Haurwitz Rachel E. (President and CEO) | Buy | 20,000 | 1.02 | 20,400 |
| 2025-02-21 | Khan Ruhi Ahmad (Chief Business Officer) | Sale | 3,564 | 1.35 | 4,811 |
| 2025-02-21 | Kanner Steven (Chief Scientific Officer) | Sale | 3,564 | 1.35 | 4,811 |
| 2025-02-21 | Mcclung Barbara G (Chief Legal Officer) | Sale | 3,564 | 1.35 | 4,811 |
| 2025-01-29 | Ryali Sriram (Chief Financial Officer) | Buy | 17,360 | 1.42 | 24,651 |
| 2024-02-06 | Kanner Steven (Chief Scientific Officer) | Option Ex | 30,577 | 2.69 | 82,252 |
| 2023-06-08 | Haurwitz Rachel E. (President and CEO) | Option Ex | 10,000 | 2.96 | 29,600 |
| 2023-03-20 | Haurwitz Rachel E. (President and CEO) | Option Ex | 10,000 | 2.96 | 29,600 |
| 2023-01-19 | Rizvi Syed Ali-aamir (Chief Medical Officer) | Sale | 5,627 | 6.31 | 35,506 |
| 2022-12-02 | Kanner Steven (Chief Scientific Officer) | Option Ex | 64,203 | 2.69 | 172,704 |
| 2022-10-06 | Fischesser Ryan (VP of Finance and Controller) | Sale | 10,000 | 10.80 | 107,960 |
| 2022-10-06 | Fischesser Ryan (VP of Finance and Controller) | Option Ex | 5,678 | 3.40 | 19,305 |
| 2022-09-15 | Mcclung Barbara G (Chief Legal Officer) | Option Ex | 27,595 | 2.69 | 74,230 |
| 2022-05-13 | Kanner Steven (Chief Scientific Officer) | Option Ex | 74,420 | 2.25 | 167,445 |
| 2022-05-09 | Haurwitz Rachel E. (President and CEO) | Option Ex | 10,000 | 2.96 | 29,600 |
| 2022-05-05 | Fischesser Ryan (VP of Finance and Controller) | Option Ex | 2,274 | 3.40 | 7,731 |
| 2022-03-15 | Fischesser Ryan (VP of Finance and Controller) | Option Ex | 2,274 | 3.40 | 7,731 |
| 2022-03-04 | Kanner Steven (Chief Scientific Officer) | Option Ex | 10,720 | 3.40 | 36,448 |
| 2022-02-08 | O'byrne Jason (Chief Financial Officer) | Option Ex | 24,336 | 4.11 | 100,020 |
| 2022-01-26 | Haurwitz Rachel E. (President and CEO) | Option Ex | 10,000 | 2.96 | 29,600 |
| 2022-01-11 | Fischesser Ryan (VP of Finance and Controller) | Buy | 7,387 | 3.40 | 25,115 |
| 2021-12-20 | Fischesser Ryan (VP of Finance and Controller) | Buy | 1,136 | 2.69 | 3,055 |
| 2021-12-07 | Mcclung Barbara G (Chief Legal Officer) | Buy | 6,127 | 2.69 | 16,481 |
| 2021-10-20 | Mcclung Barbara G (Chief Legal Officer) | Buy | 9,219 | 2.69 | 24,799 |
| 2021-10-12 | Kanner Steven (Chief Scientific Officer) | Buy | 114,860 | 2.10 | 241,550 |
| 2021-10-11 | Fischesser Ryan (VP of Finance and Controller) | Buy | 1,746 | 2.69 | 4,696 |
Insider trading activities including stock purchases, stock sales, and option exercises of CRBU listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Caribou Biosciences, Inc. (symbol CRBU, CIK number 1619856) see the Securities and Exchange Commission (SEC) website.